Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Viking Therapeutics, Inc. - Common Stock
(NQ:
VKTX
)
33.39
-0.13 (-0.39%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 21, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Viking Therapeutics, Inc. - Common Stock
< Previous
1
2
...
23
24
25
26
27
28
29
30
Next >
7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution
↗
February 14, 2024
Obesity drug sales boomed in 2023 and will continue in 2024. That could make these weight loss stocks even more attractive.
Via
InvestorPlace
Amazon, Progress Software And 2 Other Stocks Insiders Are Selling
↗
February 12, 2024
The Nasdaq 100 closed higher by 1% on Friday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in February 2024
↗
February 08, 2024
With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider.
Via
InvestorPlace
Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug
↗
February 08, 2024
The company is looking to take on Eli Lilly's tirzepatide as both a shot and a pill for weight loss.
Via
Investor's Business Daily
Arm Holdings Posts Upbeat Results, Joins Hershey, CyberArk Software, Wynn Resorts And Other Big Stocks Moving Higher On Thursday
↗
February 08, 2024
U.S. stocks traded mixed, with the Dow Jones gaining around 20 points on Thursday.
Via
Benzinga
Topics
Stocks
Recap: Viking Therapeutics Q4 Earnings
↗
February 07, 2024
Via
Benzinga
Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
February 08, 2024
Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results.
Via
Benzinga
Earnings Scheduled For February 7, 2024
↗
February 07, 2024
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million.
Via
Benzinga
Earnings Preview: Viking Therapeutics
↗
February 06, 2024
Via
Benzinga
1 Under-the-Radar Stock That Could Triple By 2030
↗
November 04, 2023
This small-cap biotech stock is going to compete against some giants.
Via
The Motley Fool
Earnings Scheduled For October 25, 2023
↗
October 25, 2023
Companies Reporting Before The Bell • Deutsche Bank (NYSE:DB) is estimated to report quarterly earnings at $0.52 per share on revenue of $7.65 billion.
Via
Benzinga
The 3 Best Biotech Stocks to Invest in for Big Gains in 2024
↗
February 02, 2024
These pivotal biotech stocks for gains are charting the future of medicine and investment growth in 2024 offering powerful returns
Via
InvestorPlace
2 Rising Biotechs That Could Become the Next Novo Nordisk
↗
January 29, 2024
Each of these companies has a big market in its sights.
Via
The Motley Fool
3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024
↗
January 22, 2024
Biotech stocks are some of the most exciting opportunities on the market. Find the right ones with catalysts, and you could make a fortune.
Via
InvestorPlace
2 Stocks That Could Soar This Year: Are They Buys?
↗
January 22, 2024
They might perform well in 2024, but how will they do beyond that?
Via
The Motley Fool
2 biotechs with promising weight-loss drugs coming
January 16, 2024
Clinical weight-loss medications have been making headlines as GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co.
Via
MarketBeat
The 3 Best Biotech Stocks to Buy in January 2024
↗
January 09, 2024
Biotech is still one of the most exciting investments on the market, creating substantial opportunities for some of the best biotech stocks.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
↗
January 09, 2024
Via
Benzinga
M&A Watch: 3 Drug Maker Stocks That Could Be Acquired in 2024
↗
January 02, 2024
Lower interest rates and the low valuation of many biotech stocks are likely to result in many drug maker stocks being acquired in 2024.
Via
InvestorPlace
Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?
↗
December 12, 2023
Both of these pharma stocks could be big winners. But one stock screens as a better buy from a risk standpoint.
Via
The Motley Fool
Why Viking Therapeutics Was Crushing It This Week
↗
December 08, 2023
Nowadays, it's good to be a developer of next-generation weight loss drugs.
Via
The Motley Fool
What's Going On With Viking Therapeutics Shares Tuesday?
↗
November 14, 2023
Viking Therapeutics Inc (NASDAQ: VKTX) shares are trading higher Tuesday after the company presented new data from its Phase 2b study
Via
Benzinga
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders
October 19, 2023
EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END
Via
FinancialNewsMedia
Why Are Stocks Down Today?
↗
October 18, 2023
Stocks are down again on Wednesday as investors continue to feel the effects of several major catalysts hitting the market.
Via
InvestorPlace
Pfizer Layoffs 2023: What to Know About the Latest PFE Job Cuts
↗
October 18, 2023
Pfizer layoffs are a hot topic among PFE stock traders on Wednesday as they pour over the details of the job cuts amid a Covid slump.
Via
InvestorPlace
Topics
Workforce
Why Is Viking Therapeutics (VKTX) Stock Moving Today?
↗
October 18, 2023
Viking Therapeutics stock is on the move Wednesday as investors react to results from the company's latest clinical trial!
Via
InvestorPlace
Why Talaris Therapeutics Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
↗
October 18, 2023
Gainers Biocept, Inc. (NASDAQ: BIOC) shares surged 91.8% to $0.98 in pre-market trading after falling over 6% on Tuesday. Biocept recently filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court...
Via
Benzinga
Topics
Bankruptcy
Jim Carmer Is 'A Seller' Of This Company Because 'Elon Musk Said That He Doesn't Like That Business'
↗
October 11, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Abbott Laboratories (NYSE: ABT) is a "very good company and will be up to the—let’s say—up to the challenge. I think that’s fair.
Via
Benzinga
Consolidation In Viking Therapeutics Provides An Opportunity
↗
October 01, 2023
Viking Therapeutics Inc. (VKTX) is an innovative biotechnology company developing novel therapeutics for metabolic and endocrine diseases.
Via
Talk Markets
Canopy Growth, DocGo And Other Big Stocks Moving Lower On Monday
↗
September 18, 2023
U.S. stocks traded mostly flat on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
< Previous
1
2
...
23
24
25
26
27
28
29
30
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.